Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Crispr Therapeutics Ag (CRSP)

Crispr Therapeutics Ag (CRSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,302,477
  • Shares Outstanding, K 85,046
  • Annual Sales, $ 371,210 K
  • Annual Income, $ -153,610 K
  • EBIT $ -355 M
  • EBITDA $ -335 M
  • 60-Month Beta 1.67
  • Price/Sales 11.63
  • Price/Cash Flow N/A
  • Price/Book 1.99

Options Overview Details

View History
  • Implied Volatility 67.73% ( +3.83%)
  • Historical Volatility 41.41%
  • IV Percentile 78%
  • IV Rank 50.93%
  • IV High 89.11% on 12/07/23
  • IV Low 45.53% on 08/26/24
  • Put/Call Vol Ratio 0.53
  • Today's Volume 6,637
  • Volume Avg (30-Day) 6,247
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 67,642
  • Open Int (30-Day) 68,818

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -1.33
  • Number of Estimates 13
  • High Estimate 0.00
  • Low Estimate -1.83
  • Prior Year -1.41
  • Growth Rate Est. (year over year) +5.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.44 +13.84%
on 10/09/24
51.90 -2.52%
on 11/04/24
+5.22 (+11.51%)
since 10/04/24
3-Month
43.42 +16.51%
on 09/06/24
51.99 -2.69%
on 09/18/24
-0.52 (-1.02%)
since 08/02/24
52-Week
43.42 +16.51%
on 09/06/24
91.10 -44.47%
on 02/22/24
-0.40 (-0.78%)
since 11/03/23

Most Recent Stories

More News
3 Companies Building Tomorrow's Game-Changing Technologies

These pioneering companies are transforming delivery, medicine, and space access--potentially creating massive opportunities for early investors.

SERV : 9.45 (-5.88%)
CRSP : 50.59 (-0.33%)
RKLB : 11.25 (-1.49%)
Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers

It won't be able to be profitable without hitting its targets for both of these figures.

CRSP : 50.59 (-0.33%)
VRTX : 472.80 (+0.36%)
12 High-Growth Stocks That Could Deliver Parabolic Returns

These 12 innovative companies could deliver exponential returns over the next quarter century.

NVDA : 136.05 (+0.48%)
NVTS : 2.61 (+1.16%)
VRTX : 472.80 (+0.36%)
RKLB : 11.25 (-1.49%)
LUNR : 7.58 (-6.54%)
SERV : 9.45 (-5.88%)
ACHR : 3.24 (-1.22%)
TSLA : 242.84 (-2.47%)
CRSP : 50.59 (-0.33%)
SOUN : 5.09 (-0.97%)
APLD : 5.97 (-7.59%)
TM : 172.70 (-0.08%)
The Ultimate Biotech Stock to Buy With $50 Right Now

This company might be worth far more than many realize.

CRSP : 50.59 (-0.33%)
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma

For Immediate ReleaseChicago, IL – October 25, 2024 – Today, Zacks Equity Research discusses Exelixis, Inc, EXEL, Blueprint Medicines BPMC, CRISPR Therapeutics CRSP, Amicus Therapeutics FOLD and Verona...

FOLD : 11.33 (-1.22%)
CRSP : 50.59 (-0.33%)
VRNA : 38.15 (+9.06%)
EXEL : 34.29 (+0.50%)
BPMC : 91.88 (+1.30%)
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright

It has been a decent year for the biotech industry so far, buoyed by new drug approvals and positive regulatory/pipeline updates. The third-quarter earnings season has just kicked off, with most major...

FOLD : 11.33 (-1.22%)
CRSP : 50.59 (-0.33%)
VRNA : 38.15 (+9.06%)
EXEL : 34.29 (+0.50%)
BPMC : 91.88 (+1.30%)
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

The aggressive growth icon kicked off the new trading week by buying some of her favorite stocks.

CRSP : 50.59 (-0.33%)
DDD : 3.34 (-1.47%)
AMZN : 195.78 (-1.09%)
Why We Buy Stocks

Is fear of missing out (FOMO) controlling your portfolio?

NVDA : 136.05 (+0.48%)
AVGO : 168.55 (-0.22%)
SPOT : 377.73 (-1.76%)
VRTX : 472.80 (+0.36%)
USHY : 36.99 (+0.22%)
PLD : 113.86 (+0.41%)
RKLB : 11.25 (-1.49%)
SFT.LN : 25.000 (+2.46%)
WINA : 390.11 (+1.41%)
MCD : 292.85 (-0.80%)
CRSP : 50.59 (-0.33%)
SFTBF : 60.0000 (-1.07%)
3 Bargain Stocks to Buy in a Market That's Priced for Perfection

Yes, bargains can still be found in the stock market.

CRSP : 50.59 (-0.33%)
BRK.A : 664,750.00 (-1.95%)
BRK.B : 442.29 (-2.18%)
PFE : 27.76 (-1.17%)
AXSM : 87.25 (-1.79%)
Why I Keep Buying These 14 Incredible Growth Stocks

This diverse set of growth stocks offers tremendous opportunities in the fields of AI, space, biotech, and emerging industries.

NVDA : 136.05 (+0.48%)
NVTS : 2.61 (+1.16%)
RKLB : 11.25 (-1.49%)
KTOS : 22.99 (+0.52%)
LUNR : 7.58 (-6.54%)
ASPN : 18.25 (+1.11%)
TSM : 191.56 (-0.72%)
ACHR : 3.24 (-1.22%)
CRSP : 50.59 (-0.33%)
GE : 171.76 (+0.03%)
JOBY : 5.04 (+3.49%)
PRME : 3.96 (-1.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases.

See More

Key Turning Points

3rd Resistance Point 54.61
2nd Resistance Point 53.25
1st Resistance Point 51.92
Last Price 50.59
1st Support Level 49.24
2nd Support Level 47.88
3rd Support Level 46.55

See More

52-Week High 91.10
Fibonacci 61.8% 72.89
Fibonacci 50% 67.26
Fibonacci 38.2% 61.63
Last Price 50.59
52-Week Low 43.42

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar